The Complete Choline Guide: Best Food Sources, Supplement Forms & What the Research Shows on Memory, Heart & Liver Health

A registered dietitian’s complete, evidence-based reference for choline: every major food source ranked — organ meats, eggs, soy, seafood, and plants — infant needs, choline supplement forms, and what current research shows on cognitive aging, neurological health, cardiovascular risk, and liver disease.

Choline rarely gets the attention it deserves. It’s not a vitamin, not a mineral, and it doesn’t show up on most nutrition labels — yet it’s required for cell membrane structure, methylation, acetylcholine (a key memory and muscle-control neurotransmitter), and healthy liver function. The Institute of Medicine set an Adequate Intake of 550 mg/day for men and 425 mg/day for women, and most Americans don’t come close on either.

This guide covers every major dietary source of choline — organ meats, eggs, soy foods, seafood, meat and poultry, and plant options — ranked by content, followed by a full breakdown of infant choline requirements and a practical look at how choline supplements can close remaining gaps.

Complete Choline Food Ranking (Including Eggs & Soy)

Amounts below reflect milligrams of total choline per 100 g (roughly 3.5 oz) unless noted, based on USDA, NIH ODS, and peer-reviewed food composition data.

A note on liver: Beef and chicken liver are extraordinarily rich in preformed vitamin A as well, so most clinicians recommend limiting organ meat intake to once or twice weekly rather than eating it daily — the choline benefit is easily achieved without excess retinol exposure. If organ meats aren’t palatable on their own, a small amount blended into ground beef, meatballs, or a pâté is a well-tolerated entry point for clients working through an MRT/LEAP elimination protocol. MRT testing shows that reactive foods are highly individual — anyone can react to nearly anything — but soy and egg yolk are two of the more commonly identified reactive foods on a LEAP panel. When either comes back reactive, that same liver-forward approach — paired with wild salmon and pastured meats — remains the most efficient food-based path to adequate choline.

Where Eggs and Soy Fit In

Eggs are, gram for gram, the single most concentrated common choline source — almost entirely from the yolk, so egg-white-only preparations won’t help. Two whole eggs at breakfast provide close to 300 mg, covering roughly two-thirds of the adult AI before anything else is eaten.

Soy is the strongest plant-based choline category, but the form matters considerably: whole soybeans and edamame provide meaningfully more choline than processed soy foods like tofu, where much of the choline is lost in processing. Soy milk and soy lecithin (~48 mg per tablespoon) add smaller, supplemental amounts. For someone eating an otherwise varied diet, a combination of edamame, soy milk, and tempeh can meaningfully close the gap toward the 425–550 mg adult AI, though it typically takes larger volumes of soy foods than most people realize — closer to 3–4 cups of soy milk or 2+ cups of edamame daily to reach the full target from soy alone.

Why Choline Is Especially Critical for Babies

Choline demand is highest during the prenatal period and the first two years of life, when the brain is undergoing its most rapid rate of growth. Choline is a direct precursor to acetylcholine and to the phospholipids that build every new neuron’s membrane — and unlike adults, infants cannot rely on hepatic synthesis to make up a shortfall. The Institute of Medicine (National Academy of Medicine) has set the following Adequate Intake levels:

Here’s where it gets clinically important: research analyzing choline concentrations in breast milk and infant formula has repeatedly found a gap between what infants are estimated to need and what they typically receive. Mature human milk provides roughly 120–160 mg of choline per liter, and pooled data suggest a substantial share of exclusively breastfed infants may not reach the full AI from milk volume alone. Formula is even less consistent — one comparative analysis of term and preterm infant formulas found concentrations ranging from well below to well above breast milk levels, with most formulas failing to supply the choline forms and amounts needed to match physiological infant plasma concentrations. A related consumer-facing review of the research bluntly notes that many prenatal supplements contain little to no choline, despite the outsized role it plays in fetal and infant neurodevelopment.

This is also why maternal intake during pregnancy and lactation matters so much: choline crosses the placenta and concentrates in breast milk, meaning a mother’s own choline status is often the deciding factor in what her baby actually receives. A landmark Cornell double-blind, randomized controlled feeding trial (NCT01127022) tested this directly: 26 women beginning their third trimester were randomized to consume either 480 mg/day (near the standard AI) or 930 mg/day (roughly double) of choline through delivery, with intake tightly controlled. The results, published across multiple follow-ups, consistently favored the higher-intake group. In infancy, offspring of mothers in the 930 mg/day group showed significantly faster information processing speed, tested at 4, 7, 10, and 13 months of age. At age 7, the same children showed better sustained attention, working memory, and executive function, with the 480 mg/day group showing a measurable decline in sustained attention (a 22.9% drop in target detection across a task) compared to a slight improvement in the 930 mg/day group. A separate, ongoing 14-year follow-up study is now assessing whether these advantages persist into adolescence, with results expected in 2025–2026. A related trial using phosphatidylcholine supplementation at roughly 900 mg choline/day, started in the second trimester, similarly found measurable differences in infant brain electrophysiology by 5 weeks of age. Choline is not currently included in standard prenatal vitamins, and average intake among pregnant women runs closer to 70% of the AI — a meaningful gap given this data.

Important clinical note: The Food and Nutrition Board has not established a Tolerable Upper Intake Level for choline in infants, specifically because there isn’t sufficient safety data — meaning breast milk, formula, and age-appropriate whole foods should remain the primary choline sources for babies. Any direct infant supplementation should only be introduced under the guidance of a pediatrician or registered dietitian, not initiated independently by a caregiver.

How to Close the Gap — For Mother and Baby

• During pregnancy and lactation: Prioritize choline-dense whole foods (liver once weekly, salmon, pastured meats) alongside a prenatal that specifically lists choline, since many do not. A practitioner-grade prenatal through Fullscript can help confirm actual choline content on the label.
• Once solids begin (around 6 months): Introduce iron- and choline-rich foods like well-cooked pureed liver, egg yolk (if not restricted), and meat purees as first foods — both nutrients support the same window of rapid brain development.
• For elimination-diet clients: Soy and egg yolk are two of the more commonly reactive foods identified on MRT/LEAP testing — though reactivity is highly individual and testing can flag any food. When one or both come back reactive, organ meats and wild salmon become the most efficient way to maintain choline status without reintroducing a reactive food.

The Betaine Connection

Choline and betaine are metabolically linked: once absorbed, a portion of dietary choline is irreversibly oxidized in the liver and kidneys into betaine, which then plays its own distinct role in methylation and homocysteine metabolism. Because that conversion only runs one direction, betaine can’t be converted back into choline — meaning betaine-rich foods support methylation status but don’t substitute for choline’s other roles in acetylcholine synthesis and cell membrane structure. Betaine has its own distinct set of benefits worth understanding alongside choline, and the two nutrients are commonly found together in beef liver, wheat, beets, spinach, and quinoa — so a diet built around these foods tends to support both pathways at once.

What the Research Shows: Choline, Memory, Neurological Health & Heart Health

Age-Related Memory & Cognitive Decline

Choline’s role in brain health extends well beyond infancy. A 2025 prospective cohort study of more than 125,000 adults, published in the American Journal of Clinical Nutrition, found that moderate dietary choline intake — roughly 330–354 mg per day — was associated with lower incidence of dementia, Alzheimer’s disease, and mild cognitive impairment, independent of demographic, dietary, and lifestyle confounders. A separate 2025 analysis from the Rush Memory and Aging Project similarly linked higher dietary choline intake to a reduced risk of clinical Alzheimer’s diagnosis, less white-matter hyperintensity volume, and better overall cognitive function in older adults. Mechanistically, this tracks: acetylcholine — the neurotransmitter most directly tied to memory and learning — is synthesized directly from choline, and choline-derived phospholipids are what allow brain cell membranes to properly incorporate DHA, the omega-3 fat central to neuronal signaling.

Neurological Conditions

Given these associational findings, researchers have begun formally investigating choline supplementation as an intervention rather than just an observed dietary pattern. A systematic review protocol registered in Frontiers in Aging Neuroscience is evaluating choline supplementation specifically for Alzheimer’s disease risk reduction, and preclinical work has shown that lifelong choline supplementation attenuated Alzheimer’s-associated pathology and microglial activation in animal models. This is still an evolving area — cohort associations are not the same as proven causal treatment effects — but it adds biological plausibility to the epidemiological signal.

Choline and Heart Health Beyond TMAO

Set aside TMAO for a moment, and choline’s cardiovascular research picture is actually more favorable — though still genuinely mixed rather than uniformly positive. Choline’s clearest heart-protective mechanism runs through homocysteine: once oxidized to betaine, choline drives the remethylation of homocysteine back to methionine, and elevated homocysteine is independently linked to cardiovascular risk. A 2025 analysis of 6,765 adults in the Multi-Ethnic Study of Atherosclerosis found hyperhomocysteinemia associated with heart failure risk (more strongly for HFpEF specifically), and a Mendelian randomization study found a likely causal link between homocysteine and both heart failure and cardiomyopathy. In line with this, a 2024 dose-response meta-analysis spanning 482,778 participants found that higher choline and betaine intake was associated with lower plasma homocysteine and concluded the evidence does not support choline intake increasing mortality risk.

A cross-sectional NHANES analysis found an inverse association between dietary choline and atherosclerotic cardiovascular disease, along with a notably strong inverse relationship between choline intake and stroke risk. That same analysis, however, identified a threshold effect worth taking seriously: choline intake above roughly 342 mg/day was associated with a slightly increased risk of congestive heart failure, suggesting the choline-heart relationship may be U-shaped rather than simply “more is better” — a finding echoed by the PREDIMED cohort, which found plasma choline independently associated with increased heart failure risk. A separate 2024 Mendelian randomization study using NHANES data found choline consumption associated with reduced overall CVD risk, partially mediated through favorable body composition changes, adding a causal (not just correlational) angle to the inverse-risk findings.

Not every cardiac outcome tells the same story: a Journal of the American Heart Association study spanning three Norwegian cohorts (over 14,000 participants combined) found no consistent association between choline or betaine and atrial fibrillation risk, in contrast to the clearer signal for atherosclerotic disease — a useful reminder that “choline and heart health” isn’t a single uniform relationship across every cardiac condition. The Atherosclerosis Risk in Communities (ARIC) study remains one of the foundational cohorts establishing why choline and betaine need to be evaluated together, given their shared, interdependent pathway with folate metabolism.

Taken as a whole, this body of research supports choline’s essential role in cardiovascular health through the homocysteine pathway, with reasonably consistent inverse associations for atherosclerosis and stroke — but the heart failure threshold signal and the AF null finding are legitimate reasons to favor meeting, rather than substantially exceeding, the Adequate Intake through whole foods, rather than assuming unlimited benefit from higher and higher choline intake.

Heart Health: The TMAO Nuance

No discussion of choline and cardiovascular health is complete without addressing trimethylamine N-oxide (TMAO), a compound gut bacteria produce from dietary choline (and carnitine and betaine). Landmark research published in the New England Journal of Medicine first linked elevated TMAO to increased risk of major adverse cardiovascular events, and subsequent meta-analyses spanning tens of thousands of patients have consistently associated higher circulating TMAO with greater cardiovascular event and mortality risk, particularly in populations with chronic kidney disease. At the same time, a 2025 narrative review noted that human clinical trial data establishing TMAO as a direct causal driver of cardiovascular disease — rather than simply a correlated marker — remains limited, and TMAO production depends heavily on individual gut microbiome composition rather than choline intake alone. In practical terms: this is a reason to prioritize whole-food choline sources with a favorable overall fat and fiber profile (fish, pastured meats, legumes) and to support a healthy gut microbiome, rather than a reason to avoid choline altogether given its essential, non-negotiable role in brain and liver function.

Can Probiotics Lower TMAO?

Since TMAO is a gut-microbiota-dependent metabolite, there’s understandable interest in whether targeted probiotic strains can blunt its production — but the evidence is strain-specific, not a class effect. A systematic review of the literature identified Lactobacillus rhamnosus GG as the most consistently effective strain for lowering plasma TMAO in both human and animal studies, with Lactobacillus plantarum strains (ZDY04, LP1145) and Lactobacillus amylovorus LAM 1345 showing promise in animal models. Separately, Bifidobacterium breve and Bifidobacterium longum have been shown to attenuate choline-induced TMAO production in mice by favorably shifting gut microbiota composition, building on earlier work showing bifidobacteria levels are inversely correlated with plasma TMAO.

That said, human randomized controlled trials paint a more mixed picture than the strain-specific animal data suggest: a meta-analysis of human RCTs found that probiotic supplementation as a category did not significantly lower TMAO levels, and a controlled trial in healthy young men similarly found no significant reduction after four weeks of a general probiotic blend. A more rigorously designed double-blind RCT combining Lactobacillus acidophilus, L. rhamnosus GG, Bifidobacterium animalis, and B. longum against a phosphatidylcholine challenge remains one of the better human data points in this space, though results have not consistently replicated across studies. Beyond conventional probiotic strains, emerging research on Akkermansia muciniphila — sometimes grouped with next-generation psychobiotics — suggests it may suppress the microbial enzymes directly responsible for TMA synthesis, making it a strain to watch as this research matures.

The honest, evidence-based takeaway: don’t expect an off-the-shelf multi-strain probiotic to meaningfully move TMAO on its own. If TMAO reduction is a specific clinical goal, strain selection matters far more than simply “taking a probiotic,” and the strongest current evidence points to L. rhamnosus GG and select Bifidobacterium species — with the caveat that most of this data is still preclinical or from small human trials.

Beyond Probiotics: Other TMAO-Lowering Strategies

Probiotics are only one lever in a broader body of TMAO research. A handful of dietary compounds, pharmaceuticals, and lifestyle factors have shown measurable TMAO-lowering effects:

• Polyphenols (resveratrol, quercetin, grape pomace extract): A randomized, placebo-controlled crossover trial of a grape-pomace polyphenol formulation (Taurisolo®) found a 63.6% reduction in serum TMAO after four weeks versus 0.54% in placebo, with a follow-up trial showing reductions of roughly 50–76% at 4 and 8 weeks alongside drops in oxidized LDL — a marker directly relevant to the broader lipid picture covered in The Cholesterol Conversation We Actually Need to Have. Resveratrol alone has shown TMAO-reducing effects in animal models, though a 2024 human trial combining resveratrol with exercise training found more complex, dose-dependent metabolic shifts rather than a straightforward reduction.
• Berberine: This plant alkaloid has been shown to lower TMAO in hypertensive patients at one and three months, working in part by inhibiting the bacterial TMA lyase enzyme responsible for TMA production — the same enzymatic target several other TMAO-lowering compounds work through.
• DMB (3,3-dimethyl-1-butanol): A structural analog of choline found naturally in olive oil and balsamic vinegar, DMB non-lethally inhibits gut bacterial TMA production. In choline-fed, atherosclerosis-prone mice, DMB lowered TMAO and reduced arterial plaque formation without apparent toxicity — though human trial data is still limited.
• Mediterranean-style dietary patterns: A short-term dietary intervention trial found that shifting to a Mediterranean dietary pattern reduced plasma TMAO in healthy individuals, plausibly through its higher fiber, polyphenol, and unsaturated fat content displacing some of the substrate load for TMA-producing bacteria.
• Statins: Some research suggests statin therapy may modestly lower TMAO as a secondary effect of altering gut microbiota and bile acid metabolism, separate from their primary cholesterol-lowering mechanism.

Taken together with the probiotic research above, the clearest pattern is that fiber- and polyphenol-rich whole foods — berries, grapes, olive oil, nuts, and a generally Mediterranean-leaning pattern — currently have the best combination of mechanistic plausibility and early human data for supporting healthy TMAO metabolism, ahead of any single supplement.

Liver Health (NAFLD)

Choline’s connection to liver health is where the nutrient was first clinically identified as essential — animal models of severe choline deficiency reliably produce fatty liver and steatohepatitis nearly identical in appearance to nonalcoholic fatty liver disease (NAFLD). In humans, a NASH Clinical Research Network analysis of over 660 biopsy-confirmed NAFLD patients found that postmenopausal women with inadequate choline intake had significantly worse liver fibrosis, even after controlling for obesity, diabetes, and other NAFLD risk factors — an effect not seen in men or premenopausal women, likely reflecting estrogen’s role in the body’s ability to synthesize its own choline via the PEMT pathway. A subsequent NHANES-based analysis of U.S. adults reinforced the broader association between low choline intake and hepatic steatosis risk. This is a key reason choline deserves more attention in functional approaches to liver and metabolic health, particularly for postmenopausal women.

How Choline Supplements Can Help — And Which Form Matters

National survey data has repeatedly found that the majority of American adults fall short of the choline AI from diet alone, even before accounting for restricted diets, pregnancy, or lactation. When food alone can’t reliably close the gap — a common scenario for egg-avoidant, low-organ-meat, or plant-forward eaters — a supplement can help, but the forms are not interchangeable:

For most general wellness or prenatal use, choline bitartrate or a food-derived phosphatidylcholine is sufficient and well studied; citicoline and alpha-GPC are typically reserved for more targeted cognitive goals, given their higher cost and more stimulating effect profile for some individuals. A practitioner-grade prenatal or standalone choline supplement through Fullscript can help confirm the specific form and dose, since — as noted above — many prenatal multivitamins list little or no choline at all.

The Bottom Line

Choline is one of the most under-recognized nutrients in both prenatal and infant nutrition. Eggs and organ meats remain the most concentrated whole-food sources, soy foods offer the strongest plant-based option once volume is accounted for, and a well-chosen supplement — matched to the right form for the goal — can reliably close whatever gap remains. For babies, the margin for error is much smaller: given the documented variability in breast milk and formula choline content, working with a knowledgeable practitioner to assess maternal and infant intake is a reasonable, evidence-based precaution rather than an overreaction.